Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read More
Tag: PSA
Janssen’s Tremfya wins psoriatic arthritis approval
The drug is the first IL-23 inhibitor approved for the condition
Read More
New prostate cancer test could diagnose five years earlier
Previous urine biomarker tests have been designed specifically for single purposes such as the detection of prostate cancer on re-biopsy.
Read More
Novartis’ Cosentyx shown to inhibit joint damage in PsA
Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage.
Read More
Two new approvals for Janssen’s Simponi Aria
US regulators have expanded the scope of Janssen Biotech’s Simponi Aria to include the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
Read More
NICE nod for Novartis’ Cosentyx in PsA
The National Institute for Health and Care Excellence has published a positive Final Appraisal Determination which backs NHS use of Novartis’ Cosentyx in adults with active and progressive psoriatic arthritis.
Read More
Novartis plans head-to-head trial for Cosentyx and Humira
Novartis and Sandoz are to present new analyses indicating that their biologic Cosentyx could lead to higher responses than AbbVie’s anti-inflammatory super-blockbuster Humira in improving the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
